These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7644104)

  • 1. Starting r-HuEPO in chronic renal failure: when, why, and how?
    Koene RA; Frenken LA
    Nephrol Dial Transplant; 1995; 10 Suppl 2():35-42. PubMed ID: 7644104
    [No Abstract]   [Full Text] [Related]  

  • 2. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
    Zehnder C; Blumberg A
    Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Starting r-HuEPO in chronic renal failure: when, why, and how?
    Jacobs C
    Nephrol Dial Transplant; 1995; 10 Suppl 2():43-7. PubMed ID: 7644105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of the anaemia of chronic renal failure with recombinant human erythropoietin.
    Winearls CG
    Drugs; 1989 Sep; 38(3):342-5. PubMed ID: 2806134
    [No Abstract]   [Full Text] [Related]  

  • 5. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients.
    Boran M; Dalva I; Yazicioğlu A; Cetin S
    Nephron; 1993; 63(1):113-4. PubMed ID: 8446239
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimal route of administration of erythropoietin in chronic renal failure patients: intravenous versus subcutaneous.
    Hörl WH
    Acta Haematol; 1992; 87 Suppl 1():16-9. PubMed ID: 1574961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin therapy in patients with chronic renal failure.
    Pinevich AJ; Petersen J
    West J Med; 1992 Aug; 157(2):154-7. PubMed ID: 1441466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin.
    McMahon LP; Dawborn JK
    Am J Nephrol; 1990; 10(5):404-8. PubMed ID: 2080791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effect of recombinant human erythropoietin on anemia associated with chronic renal failure. A multi-institutional study in Japan.
    Akizawa T; Koshikawa S; Takaku F; Urabe A; Akiyama N; Mimura N; Otsubo O; Nihei H; Suzuki Y; Kawaguchi Y
    Int J Artif Organs; 1988 Sep; 11(5):343-50. PubMed ID: 3056862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daily self-administered subcutaneous erythropoietin: benefits in haemodialysis patients.
    Granolleras C; Branger B; Deschodt G; Shaldon S; Nonnast-Daniel B; Pollok M
    Contrib Nephrol; 1990; 82():49-54. PubMed ID: 2093526
    [No Abstract]   [Full Text] [Related]  

  • 12. Crossover comparison of intravenous and subcutaneous recombinant human erythropoietin in a small haemodialysis unit.
    Balkovetz DF; Frazier C; Sanders PW
    Nephrol Dial Transplant; 1998 Nov; 13(11):2979-80. PubMed ID: 9829525
    [No Abstract]   [Full Text] [Related]  

  • 13. Recombinant human erythropoietin (r-HuEPO): quality of life and other considerations.
    Tan A
    J CANNT; 1990; ():13-4. PubMed ID: 2202375
    [No Abstract]   [Full Text] [Related]  

  • 14. [Comparison of the efficacy and tolerance of recombinant human erythropoietin between intravenous and subcutaneous administration in chronic hemodialysis. Prospective multicenter study].
    Ruedin P; Stoerman C; Pechère-Bertschi A; Leski M
    Nephrologie; 1992; 13(2):87-92. PubMed ID: 1608502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of subcutaneous low-dose erythropoietin in patients with chronic renal failure despite functional iron deficiency.
    Bedani PL; Cecchetti E; Gilli P
    Nephron; 1995; 71(4):459-60. PubMed ID: 8587628
    [No Abstract]   [Full Text] [Related]  

  • 16. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients.
    Abraham PA; Opsahl JA; Rachael KM; Asinger R; Halstenson CE
    Am J Nephrol; 1990; 10(2):128-36. PubMed ID: 2349956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The observation of therapy of anemia in chronic renal failure with recombinant human erythropoietin].
    Jiang Y; Liu P; Wang EJ
    Zhonghua Nei Ke Za Zhi; 1994 Feb; 33(2):80-2. PubMed ID: 8070295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant erythropoietin in pediatrics: a clinical perspective.
    Shannon KM
    Pediatr Ann; 1990 Mar; 19(3):197-206. PubMed ID: 2181391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of erythropoietin to treat anaemia in end-stage renal disease.
    Ellis P; Ellis JA
    Prof Nurse; 1995 Apr; 10(7):448-50. PubMed ID: 7724635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
    Cowgill LD; James KM; Levy JK; Browne JK; Miller A; Lobingier RT; Egrie JC
    J Am Vet Med Assoc; 1998 Feb; 212(4):521-8. PubMed ID: 9491159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.